Author

D. E. Bussiere

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:protein structure prediction· 1 Assay:structural biology· 1

Frequent Co-Authors

A. Frommlet· 2 shared A. O. Frank· 2 shared M. Knapp· 2 shared A. Burke· 1 shared A. Fazal· 1 shared A. Godbole· 1 shared A. Proudfoot· 1 shared B. Okram· 1 shared

Activity by Year

2019-2019 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

A. Frommlet

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The Structural Basis of Indisulam-Mediated Recruitment of RBM39 to the DCAF15-DDB1-DDA1 E3 Ligase Complex

D. E. Bussiere, L. Xie, W. Shu, H. Srinivas, W. Shu, A. Burke, C. Be, J. Zhao, A. Godbole, D. King, R. G. Karki, V. Hornak, F. Xu, J. Cobb, N. Carte, , J. Paulk

This study determines the structure of the DCAF15-DDB1-DDA1-Indisulam-RBM39 complex, revealing how Indisulam promotes RBM39 degradation via a novel degron motif.

bioRxiv · Aug 16, 2019Biophysics

A VP2/3-derived peptide exhibits potent antiviral activity against BK and JC polyomaviruses by targeting a novel VP1 binding site

J. R. Kane, S. Fong, J. Shaul, A. Frommlet, A. O. Frank, M. Knapp, D. E. Bussiere, P. Kim, E. Ornelas, C. Cuellar, J. R. Abend, C. A. Wartchow

The paper identifies a VP2/3-derived peptide that inhibits BK and JC polyomaviruses by binding to a novel VP1 pore site, showing potent antiviral activity with low nanomolar affinity.

bioRxiv · Aug 8, 2019 · PreprintMicrobiology

Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation

J. N. Spradlin, X. Hu, C. C. Ward, S. M. Brittain, M. D. Jones, L. Ou, M. To, A. Proudfoot, E. Ornleas, M. Woldegiorgis, J. A. Olzmann, D. E. Bussiere, J. R. Thomas, J. A. Tallarico, J. M. McKenna, , D. K. Nomura

This study identifies nimbolide's mechanism of action by showing it targets RNF114, leading to stabilization of p21 and inhibition of breast cancer cell proliferation.

bioRxiv · Apr 9, 2019Cancer Biology